Drug Profile
BMS 777607
Alternative Names: ASLAN-002; BMS-777607; BMS-797669Latest Information Update: 15 Sep 2020
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer ASLAN Pharmaceuticals; Bristol-Myers Squibb; Huntsman Cancer Institute
- Class Aminopyridines; Antineoplastics; Dihydropyridines; Pyridones; Small molecules
- Mechanism of Action Proto-oncogene protein c-met inhibitors; RON protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Cancer; Gastric cancer; Head and neck cancer; Osteoporosis; Prostate cancer; Renal cell carcinoma
Most Recent Events
- 15 Sep 2020 Discontinued - Phase-I for Osteoporosis in USA (PO) (Bristol-Myers Squibb pipeline, September 2020) (ASLAN Pharmaceuticals, September 2020)
- 15 Sep 2020 Discontinued - Phase-II for Breast cancer (PO) (Bristol-Myers Squibb pipeline, September 2020) (ASLAN Pharmaceuticals, September 2020)
- 15 Sep 2020 Discontinued - Phase-II for Gastric cancer (Late-stage disease, Metastatic disease) in Australia (PO) (Bristol-Myers Squibb pipeline, September 2020) (ASLAN Pharmaceuticals, September 2020)